Volume 12 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(3): 302-308
Wang Meixi, Zhao Yuanyuan, Yang Bo, et al. Comparison of clinical efficacy of different anti-tumor therapies for recurrence and metastasis after liver transplantation for liver cancer[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 302-308. doi: 10.3969/j.issn.1674-7445.2021.03.008
Citation: Wang Meixi, Zhao Yuanyuan, Yang Bo, et al. Comparison of clinical efficacy of different anti-tumor therapies for recurrence and metastasis after liver transplantation for liver cancer[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 302-308. doi: 10.3969/j.issn.1674-7445.2021.03.008
shu

Comparison of clinical efficacy of different anti-tumor therapies for recurrence and metastasis after liver transplantation for liver cancer

doi: 10.3969/j.issn.1674-7445.2021.03.008

  • Organ Transplantation Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, Key Laboratory of Organ Transplantation of National Health Commission of China, Key Laboratory of Organ Transplantation of Chinese Academy of Medical Sciences, Wuhan 430030, China

More Information
  • Corresponding author: Chen Zhishui, Email: zschen@tjh.tjmu.edu.cn
  • Received Date: 2021-01-03
    Available Online: 2021-05-19
  • Publish Date: 2021-05-15
    Abstract
  •   Objective  To analyze the clinical efficacy of different anti-tumor therapies for recurrence and metastasis after liver transplantation for primary liver cancer (liver cancer).  Methods  Clinical data of 145 recipients undergoing liver transplantation for liver cancer were retrospectively analyzed. The overall survival and recurrence and metastasis after liver transplantation for liver cancer were analyzed. The clinical efficacy of different anti-tumor therapies for recipients with recurrence and metastasis were compared.  Results  Sixty-five recipients (44.8%) developed recurrence and metastasis. The median recurrence time was 6 months. Among them, 1 case underwent secondary liver transplantation after recurrence and died of intestinal perforation. Twenty-four recipients (37%) received targeted drug therapy with a median tumor-bearing survival of 22 months. Eleven recipients (17%) received radiotherapy or chemotherapy with a median tumor-bearing survival of 11 months. Nine recipients (14%) received local treatment (surgical resection or radiofrequency ablation), and the median tumor-bearing survival was 8 months. Twenty recipients (31%) abandoned anti-tumor therapy, and the median tumor-bearing survival was 3 months. The tumor-bearing survival of recipients receiving anti-tumor therapy was significantly longer than that of recipients without anti-tumor therapy (P < 0.001). The tumor-bearing survival of recipients receiving targeted drug therapy was significantly longer than that of those receiving other anti-tumor therapies (P=0.03). The tumor-bearing survival of recipients receiving local treatment, radiotherapy and chemotherapy was considerably longer than that of those who abandoned anti-tumor therapy (P=0.004).  Conclusions  Surgical resection and radiofrequency ablation are the optimal therapies for recipients with recurrence and metastasis after liver transplantation for liver cancer. For recipients with multi-focal tumors who fail to receive local treatment, those receiving targeted drug therapy obtain the longest survival. In addition, radiotherapy and chemotherapy can also prolong the survival of recipients with recurrence and metastasis.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
    [2]
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [3]
    LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.
    [4]
    KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [5]
    KULIK L, EL-SERAG HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2): 477-491. DOI: 10.1053/j.gastro.2018.08.065.
    [6]
    RAHBARI NN, MEHRABI A, MOLLBERG NM, et al. Hepatocellular carcinoma: current management and perspectives for the future[J]. Ann Surg, 2011, 253(3): 453-469. DOI: 10.1097/SLA.0b013e31820d944f.
    [7]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2.
    [8]
    KANNEGANTI M, MAHMUD N, KAPLAN DE, et al. Survival benefit of liver transplantation for hepatocellular carcinoma[J]. Transplantation, 2020, 104(1): 104-112. DOI: 10.1097/TP.0000000000002816.
    [9]
    AGOPIAN VG, HARLANDER-LOCKE M, ZARRINPAR A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427. DOI: 10.1016/j.jamcollsurg.2014.12.025.
    [10]
    ZIMMERMAN MA, GHOBRIAL RM, TONG MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators[J]. Arch Surg, 2008, 143(2): 182-188. DOI: 10.1001/archsurg.2007.39.
    [11]
    中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008

    Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018 edition)[J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
    [12]
    王征, 周俭. 中国肝癌肝移植现状及展望[J/CD]. 实用器官移植电子杂志, 2019, 7(1): 1-3. DOI:10.3969/j.issn.2095-5332.2019.01.001.

    WANG Z, ZHOU J. Current status and prospect of liver transplantation for hepatocellular carcinoma in China[J/CD]. Pract J Organ Transplant (Electr Vers), 2019, 7(1): 1-3. DOI:10.3969/j.issn.2095-5332.2019.01.001.
    [13]
    PARK JW, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9): 2155-2166. DOI: 10.1111/liv.12818.
    [14]
    陈晓, 蔡建强. 《原发性肝癌诊疗规范(2017年版)》解读[J/CD]. 肝癌电子杂志, 2017, 4(3): 1-5. DOI:10.3969/j.issn.2095-7815.2017.03.002.

    CHEN X, CAI JQ. Interpretation of diagnosis and treatment specification for primary liver cancer (2017 edition)[J/CD]. Electr J Liver Tumor, 2017, 4(3): 1-5. DOI:10.3969/j.issn.2095-7815.2017.03.002.
    [15]
    汪国营. 肝癌肝移植相关热点问题探讨[J]. 中山大学学报(医学科学版), 2021, 42(1): 17-23.

    WANG GY. Hot issues related to liver transplantation for hepatocellular carcinoma[J]. J Sun Yat-sen Univ (Med Sci), 2021, 42(1): 17-23.
    [16]
    BARAZANI Y, HIATT JR, TONG MJ, et al. Chronic viral hepatitis and hepatocellular carcinoma[J]. World J Surg, 2007, 31(6): 1243-1248. DOI: 10.1007/s00268-007-9041-3.
    [17]
    BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/SLA.0000000000001894.
    [18]
    DE'ANGELIS N, LANDI F, CARRA MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review[J]. World J Gastroenterol, 2015, 21(39): 11185-11198. DOI: 10.3748/wjg.v21.i39.11185.
    [19]
    CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7.
    [20]
    MARTIN RC 2ND, BRUENDERMAN E, COHN A, et al. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry[J]. Am J Surg, 2017, 213(4): 688-695. DOI: 10.1016/j.amjsurg.2016.10.006.
    [21]
    TOMONARI T, SATO Y, TANI J, et al. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: a propensity score-matched analysis[J]. Hepatol Res, 2021, 51(4): 472-481. DOI: 10.1111/hepr.13597.
    [22]
    李凯. 复杂肝癌病例热消融治疗的策略和技巧[J]. 中山大学学报(医学科学版), 2019, 40(6): 814-820. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201906003.htm

    LI K. Treatment skills of thermal ablation in complicated hepatocellular carcinoma cases[J]. J Sun Yat-sen Univ (Med Sci), 2019, 40(6): 814-820. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201906003.htm
    [23]
    史瑶平, 池嘉昌, 施东华, 等. 局部消融治疗术后单发复发肝细胞癌长期生存研究[J]. 中国实用外科杂志, 2020, 40(6): 710-714. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.19.

    SHI YP, CHI JC, SHI DH, et al. Long-term survival of local ablation for single recurrent hepatocellular carcinoma after liver resection[J]. Chin J Pract Surg, 2020, 40(6): 710-714. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.19.
    [24]
    徐肖静, 吴俊, 李惠, 等. 超声造影引导常规超声检查阴性复发性肝细胞性肝癌射频消融近期疗效分析[J]. 实用医学杂志, 2018, 34(3): 401-405. DOI: 10.3969/j.issn.1006-5725.2018.03.015.

    XU XJ, WU J, LI H, et al. Contrast-enhanced ultrasound guided radiofrequency ablation for conventional ultrasound negative recur-rent hepatocellular carcinoma: analysis of the recent therapeutic efficacy[J]. J Pract Med, 2018, 34(3): 401-405. DOI: 10.3969/j.issn.1006-5725.2018.03.015.
    [25]
    SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6.
    [26]
    吴珺艺, 孙红成, 彭志海. 肝癌肝移植术后辅助化疗的临床意义及应用[J]. 国际外科学杂志, 2010, 37(2): 112-115. DOI: 10.3760/cma.j.issn.1673-4203.2010.02.013.

    WU JY, SUN HC, PENG ZH. Adjuvant chemotherapy in hepatocellular carcinoma after liver transplantation[J]. Int J Surg, 2010, 37(2): 112-115. DOI: 10.3760/cma.j.issn.1673-4203.2010.02.013.
    [27]
    WANG MX, CHEN D, ZHAO YY, et al. Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 378-383. DOI: 10.1016/j.hbpd.2020.06.008.
    [28]
    曾昭冲. 肝癌立体定向放疗是值得探索的根治性方法[J]. 肝脏, 2020, 25(7): 665-667. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007005.htm

    ZENG ZC. Stereotactic radiotherapy for hepatocellular carcinoma is a radical method worth exploring[J]. Chin Hepatol, 2020, 25(7): 665-667. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007005.htm
    [29]
    YEUNG CSY, CHIANG CL, WONG NSM, et al. Palliative liver radiotherapy (RT) for symptomatic hepatocellular carcinoma (HCC)[J]. Sci Rep, 2020, 10(1): 1254. DOI: 10.1038/s41598-020-58108-1.
    [30]
    CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10): 1039-1049. DOI: 10.1111/tri.12372.
    [31]
    GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10): 1260-1273. DOI: 10.1111/apt.15253.
    [32]
    LING S, FENG T, ZHAN Q, et al. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria[J]. Ann Transl Med, 2020, 8(4): 80. DOI: 10.21037/atm.2020.01.10.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (385) PDF downloads(69) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return